Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APREA THERAPEUTICS, INC.

(APRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Mixed In Premarket Trading

06/16/2021 | 09:17am EDT


ę MT Newswires 2021
All news about APREA THERAPEUTICS, INC.
07/21APREA THERAPEUTICS : Phase 2 Trial of Eprenetapopt With Azacitidine Yields Posit..
MT
07/21APREA THERAPEUTICS : Announces Positive Results from Phase 2 Trial of Eprenetapo..
AQ
07/21Aprea Therapeutics, Inc. Announces Positive Results from Phase 2 Trial of Epr..
CI
06/25APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell Small Cap Complet..
CI
06/25APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 3000 Index
CI
06/25APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 3000E Growth Inde..
CI
06/25APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell Microcap Growth I..
CI
06/25APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell Small Cap Comp Gr..
CI
06/25APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2000 Index
CI
06/25APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2000 Dynamic Inde..
CI
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -38,9 M - -
Net cash 2021 79,0 M - -
P/E ratio 2021 -2,44x
Yield 2021 -
Capitalization 90,3 M 90,3 M -
EV / Sales 2021 -
EV / Sales 2022 -28,1x
Nbr of Employees 11
Free-Float 89,9%
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 4,26 $
Average target price 7,00 $
Spread / Average Target 64,3%
EPS Revisions
Managers and Directors
Christian S. Schade Chairman, President & Chief Executive Officer
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars AbrahmsÚn Chief Scientific Officer & Senior Vice President
Johan Rutger Christenson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-13.41%90
MODERNA, INC.214.44%131 902
LONZA GROUP AG20.01%55 520
IQVIA HOLDINGS INC.35.73%46 608
CELLTRION, INC.-26.60%31 131
SEAGEN INC.-17.54%26 209